Veru Inc.: Veru Reports Fiscal 2023 First Quarter Financial

Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies Presented late-breaker oral presentation at IDWeek; sabizabulin treatment

Related Keywords

Miami , Florida , United States , South Korea , United Kingdom , Australia , Canada , Korea , Mitchell Steiner , Samuel Fisch , Hannah Gendel , Schwierige Zeiten , Eli Lilly , Sexual Health Program Updates , Oncology Program Updates , Canada Health , European Union Medicines Agency , Nasdaq , Australia Therapeutic Goods Administration , European Union , Veru Inc , Korea Ministry Of Food , Drug Administration , Infectious Disease Program Updates , Regulatory Agency , Company Form , Exchange Commission , Corporate Communications , Chief Executive Officer , Novel Oralmicrotubule Disruptor , Hospitalized Moderate , High Risk , Acute Respiratory Distress Syndrome , European Medicines Agency , Therapeutic Goods Administration , Health Canada , Drug Safety , Infectious Disease Week , Combination Therapy , Line Treatment , Metastatic Castration , Antagonist Peptide , Month Subcutaneous Depot Formulation , Androgen Deprivation Therapy , Advanced Prostate Cancer , Health Program Updates , New Treatment , Benign Prostatic Hyperplasia , Quarter Financial Summary , Private Securities Litigation Reform Act , Fast Track , Investor Relations , Consolidated Statements , Tveru , Reports , Iscal , 023 , First , Quarter , Financial , Results ,